Dose-response effects of exercise on insulin among colon cancer survivors

Justin C. Brown, Michael R. Rickels, Andrea B. Troxel, Babette S. Zemel, Nevena Damjanov, Bonnie Ky, Andrew D. Rhim, Anil K. Rustgi, Kerry S. Courneya, Kathryn Schmitz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Physical activity is associated with a lower risk of disease recurrence among colon cancer survivors. The pathways through which physical activity may alter disease outcomes are unknown, but may include changes in metabolic growth factors, such as insulin. Between January 2015 and August 2015, 39 stage I-III colon cancer survivors were randomized to one of the three groups: usual care control, 150 min/week of aerobic exercise (low-dose) and 300 min/week of aerobic exercise (high-dose) for six months. The pre-specified key metabolic growth factor outcome was fasting insulin. Insulin resistance was quantified using the homeostatic model assessment. Mean age was 56.5 ± 10.0 years, 51% had stage III disease, 72% were treated with chemotherapy and the mean time since finishing treatment was 10.9 ± 6.1 months. Over six months, the low-dose group completed 141.5 ± 9.9 min/week of aerobic exercise, and the high-dose group completed 247.2 ± 10.7 min/week of aerobic exercise. Fasting insulin concentrations decreased 7.4 ± 9.4 pmol/L in the control group, 28.0 ± 8.3 pmol/L in the low-dose group and 20.7 ± 9.3 pmol/L in the high-dose group (nonlinear Ptrend = 0.042). Insulin resistance decreased 0.11 ± 0.20 in the control group, 0.63 ± 0.17 in the low-dose group and 0.43 ± 0.19 in the high-dose group (nonlinear Ptrend = 0.012). Aerobic exercise reduces insulin concentrations and insulin resistance among patients with stage I-III colon cancer. Prescribing 150 min/week of aerobic exercise may be sufficient for reducing insulin concentrations and insulin resistance, which may partially mediate the relationship between physical activity and colon cancer prognosis.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalEndocrine-Related Cancer
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Colonic Neoplasms
Survivors
Exercise
Insulin
Insulin Resistance
Fasting
Intercellular Signaling Peptides and Proteins
Control Groups
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Brown, J. C., Rickels, M. R., Troxel, A. B., Zemel, B. S., Damjanov, N., Ky, B., ... Schmitz, K. (2018). Dose-response effects of exercise on insulin among colon cancer survivors. Endocrine-Related Cancer, 25(1), 11-19. https://doi.org/10.1530/ERC-17-0377
Brown, Justin C. ; Rickels, Michael R. ; Troxel, Andrea B. ; Zemel, Babette S. ; Damjanov, Nevena ; Ky, Bonnie ; Rhim, Andrew D. ; Rustgi, Anil K. ; Courneya, Kerry S. ; Schmitz, Kathryn. / Dose-response effects of exercise on insulin among colon cancer survivors. In: Endocrine-Related Cancer. 2018 ; Vol. 25, No. 1. pp. 11-19.
@article{19d2f22abf60439cb8b71cbc03a5dd2c,
title = "Dose-response effects of exercise on insulin among colon cancer survivors",
abstract = "Physical activity is associated with a lower risk of disease recurrence among colon cancer survivors. The pathways through which physical activity may alter disease outcomes are unknown, but may include changes in metabolic growth factors, such as insulin. Between January 2015 and August 2015, 39 stage I-III colon cancer survivors were randomized to one of the three groups: usual care control, 150 min/week of aerobic exercise (low-dose) and 300 min/week of aerobic exercise (high-dose) for six months. The pre-specified key metabolic growth factor outcome was fasting insulin. Insulin resistance was quantified using the homeostatic model assessment. Mean age was 56.5 ± 10.0 years, 51{\%} had stage III disease, 72{\%} were treated with chemotherapy and the mean time since finishing treatment was 10.9 ± 6.1 months. Over six months, the low-dose group completed 141.5 ± 9.9 min/week of aerobic exercise, and the high-dose group completed 247.2 ± 10.7 min/week of aerobic exercise. Fasting insulin concentrations decreased 7.4 ± 9.4 pmol/L in the control group, 28.0 ± 8.3 pmol/L in the low-dose group and 20.7 ± 9.3 pmol/L in the high-dose group (nonlinear Ptrend = 0.042). Insulin resistance decreased 0.11 ± 0.20 in the control group, 0.63 ± 0.17 in the low-dose group and 0.43 ± 0.19 in the high-dose group (nonlinear Ptrend = 0.012). Aerobic exercise reduces insulin concentrations and insulin resistance among patients with stage I-III colon cancer. Prescribing 150 min/week of aerobic exercise may be sufficient for reducing insulin concentrations and insulin resistance, which may partially mediate the relationship between physical activity and colon cancer prognosis.",
author = "Brown, {Justin C.} and Rickels, {Michael R.} and Troxel, {Andrea B.} and Zemel, {Babette S.} and Nevena Damjanov and Bonnie Ky and Rhim, {Andrew D.} and Rustgi, {Anil K.} and Courneya, {Kerry S.} and Kathryn Schmitz",
year = "2018",
month = "1",
day = "1",
doi = "10.1530/ERC-17-0377",
language = "English (US)",
volume = "25",
pages = "11--19",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "1",

}

Brown, JC, Rickels, MR, Troxel, AB, Zemel, BS, Damjanov, N, Ky, B, Rhim, AD, Rustgi, AK, Courneya, KS & Schmitz, K 2018, 'Dose-response effects of exercise on insulin among colon cancer survivors', Endocrine-Related Cancer, vol. 25, no. 1, pp. 11-19. https://doi.org/10.1530/ERC-17-0377

Dose-response effects of exercise on insulin among colon cancer survivors. / Brown, Justin C.; Rickels, Michael R.; Troxel, Andrea B.; Zemel, Babette S.; Damjanov, Nevena; Ky, Bonnie; Rhim, Andrew D.; Rustgi, Anil K.; Courneya, Kerry S.; Schmitz, Kathryn.

In: Endocrine-Related Cancer, Vol. 25, No. 1, 01.01.2018, p. 11-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose-response effects of exercise on insulin among colon cancer survivors

AU - Brown, Justin C.

AU - Rickels, Michael R.

AU - Troxel, Andrea B.

AU - Zemel, Babette S.

AU - Damjanov, Nevena

AU - Ky, Bonnie

AU - Rhim, Andrew D.

AU - Rustgi, Anil K.

AU - Courneya, Kerry S.

AU - Schmitz, Kathryn

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Physical activity is associated with a lower risk of disease recurrence among colon cancer survivors. The pathways through which physical activity may alter disease outcomes are unknown, but may include changes in metabolic growth factors, such as insulin. Between January 2015 and August 2015, 39 stage I-III colon cancer survivors were randomized to one of the three groups: usual care control, 150 min/week of aerobic exercise (low-dose) and 300 min/week of aerobic exercise (high-dose) for six months. The pre-specified key metabolic growth factor outcome was fasting insulin. Insulin resistance was quantified using the homeostatic model assessment. Mean age was 56.5 ± 10.0 years, 51% had stage III disease, 72% were treated with chemotherapy and the mean time since finishing treatment was 10.9 ± 6.1 months. Over six months, the low-dose group completed 141.5 ± 9.9 min/week of aerobic exercise, and the high-dose group completed 247.2 ± 10.7 min/week of aerobic exercise. Fasting insulin concentrations decreased 7.4 ± 9.4 pmol/L in the control group, 28.0 ± 8.3 pmol/L in the low-dose group and 20.7 ± 9.3 pmol/L in the high-dose group (nonlinear Ptrend = 0.042). Insulin resistance decreased 0.11 ± 0.20 in the control group, 0.63 ± 0.17 in the low-dose group and 0.43 ± 0.19 in the high-dose group (nonlinear Ptrend = 0.012). Aerobic exercise reduces insulin concentrations and insulin resistance among patients with stage I-III colon cancer. Prescribing 150 min/week of aerobic exercise may be sufficient for reducing insulin concentrations and insulin resistance, which may partially mediate the relationship between physical activity and colon cancer prognosis.

AB - Physical activity is associated with a lower risk of disease recurrence among colon cancer survivors. The pathways through which physical activity may alter disease outcomes are unknown, but may include changes in metabolic growth factors, such as insulin. Between January 2015 and August 2015, 39 stage I-III colon cancer survivors were randomized to one of the three groups: usual care control, 150 min/week of aerobic exercise (low-dose) and 300 min/week of aerobic exercise (high-dose) for six months. The pre-specified key metabolic growth factor outcome was fasting insulin. Insulin resistance was quantified using the homeostatic model assessment. Mean age was 56.5 ± 10.0 years, 51% had stage III disease, 72% were treated with chemotherapy and the mean time since finishing treatment was 10.9 ± 6.1 months. Over six months, the low-dose group completed 141.5 ± 9.9 min/week of aerobic exercise, and the high-dose group completed 247.2 ± 10.7 min/week of aerobic exercise. Fasting insulin concentrations decreased 7.4 ± 9.4 pmol/L in the control group, 28.0 ± 8.3 pmol/L in the low-dose group and 20.7 ± 9.3 pmol/L in the high-dose group (nonlinear Ptrend = 0.042). Insulin resistance decreased 0.11 ± 0.20 in the control group, 0.63 ± 0.17 in the low-dose group and 0.43 ± 0.19 in the high-dose group (nonlinear Ptrend = 0.012). Aerobic exercise reduces insulin concentrations and insulin resistance among patients with stage I-III colon cancer. Prescribing 150 min/week of aerobic exercise may be sufficient for reducing insulin concentrations and insulin resistance, which may partially mediate the relationship between physical activity and colon cancer prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85042542404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042542404&partnerID=8YFLogxK

U2 - 10.1530/ERC-17-0377

DO - 10.1530/ERC-17-0377

M3 - Article

C2 - 29018055

AN - SCOPUS:85042542404

VL - 25

SP - 11

EP - 19

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -

Brown JC, Rickels MR, Troxel AB, Zemel BS, Damjanov N, Ky B et al. Dose-response effects of exercise on insulin among colon cancer survivors. Endocrine-Related Cancer. 2018 Jan 1;25(1):11-19. https://doi.org/10.1530/ERC-17-0377